PNB-001Phase 3 application submitted
Ulcerative Colitis and Crohn's Disease
- Phase II clinical trials completed for both indications with significant results.
- Phase III clinical trial application for Ulcerative Colitis submitted to DCGI.
PNB Vesper Life Science, Kochi
To become a recognized research-driven biopharmaceutical organization dedicated to discovering innovative medicines for serious diseases and unmet medical needs.
To identify, investigate, and advance novel drug candidates through focused research, scientific collaboration, and systematic evaluation, with the long-term goal of contributing to meaningful improvements in patient care.
A simplified representation of PNB Vesper's discovery-to-development approach.
6 molecules cover oncology, immune and inflammatory disease, metabolic disease, and CNS and addiction
Select a molecule to see the indications it is being developed for
All 14 molecule–indication links are shown.
The most advanced programme for each molecule, from the pipeline. The full pipeline lists 14 molecule–indication programmes
PNB-001, our lead molecule, is Phase 3-ready for Ulcerative Colitis, Phase 2-ready for Type 2 Diabetes, and has advanced to Phase 3 clinical development for COVID-19
COVID-19 Lung Inflammation
Ulcerative Colitis
Crohn's Disease
Pancreatic Cancer
Colon Cancer
PNB-001 · Phase 2 · Ulcerative Colitis
Patients responding after 28 days, as an add-on to mesalamine
| Treatment arm | Patients responding |
|---|---|
| Mesalamine alone | 4 of 9 (44%) |
| Mesalamine + PNB-001 50 mg | 5 of 9 (55%) |
| Mesalamine + PNB-001 100 mg | 8 of 9 (89%) |
Every PNB Vesper molecule comes from one platform, developed for more than a decade around cholecystokinin (CCK) receptors. Each is designed for a receptor subtype, CCK-A, CCK-B/gastrin or CCK-C, or to block several at once. That is how one chemistry reaches cancer, inflammation, metabolism and the brain
Explore the scienceMission 2035
To position India as a global powerhouse in discovering and developing novel, safe, and effective New Chemical Entities (NCEs) that transform the treatment of serious diseases and address critical unmet medical needs.
Read the first letters of PNB Vesper's nine core values in order and they spell the company's name.
Passionate
About our commitment to provide breakthrough therapy.
Nurture
A positive global environment, setting a model for others to follow.
Breakthrough
Technology that will lead to better drugs and therapeutics.
Value
Our customers (patients) and stakeholders with utmost respect.
Excellence
In quality and in everything we do.
Seek
New areas to innovate and grow.
Profitable
And sustainable growth.
Ethics
In every step of our way.
Respect
Our partners and associates.
For clinical collaboration, licensing, co-development, investment or media enquiries, the team welcomes the conversation.
info@